PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
17.83%
Net income growth at 50-75% of CRWD's 30.05%. Martin Whitman would worry about lagging competitiveness unless expansions are planned.
-1.12%
Negative yoy D&A while CRWD is 6.21%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167.19%
Both reduce yoy usage, with CRWD at -200.00%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167.19%
Negative yoy usage while CRWD is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
392.94%
Well above CRWD's 14.15%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-16.76%
Both yoy CFO lines are negative, with CRWD at -13.35%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-27.36%
Negative yoy CapEx while CRWD is 64.44%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
34.64%
Purchases well above CRWD's 31.64%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
No Data
No Data available this quarter, please select a different quarter.
-1759.09%
Both yoy lines negative, with CRWD at -9.26%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-9.40%
We reduce yoy invests while CRWD stands at 52.10%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-20.89%
Both yoy lines negative, with CRWD at -200.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
46.83%
Buyback growth of 46.83% while CRWD is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.